ArticleDrugs2016
Lusutrombopag: First Global Approval.
Article in Drugs, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 75 citations in OpenAlex.
- Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update.Hepatology international · 2017Guideline
- Lusutrombopag for thrombocytopenia in Chinese patients with chronic liver disease undergoing invasive procedures.Hepatology international · 2023Trial
- Evaluation of drug-drug interaction of lusutrombopag, a thrombopoietin receptor agonist, via metabolic enzymes and transporters.European journal of clinical pharmacology · 2020Trial
- Romiplostim Treatment of Chemotherapy-Induced Thrombocytopenia.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2019Trial
- Lusutrombopag for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Invasive Procedures (L-PLUS 2).Hepatology (Baltimore, Md.) · 2019Trial
- Repurposing lusutrombopag: unveiling anti-Staphylococcus aureus activity in a novel oral thrombopoietin receptor agonist.BMC microbiology · 2026Article
- Cancer treatment-induced thrombocytopenia: diagnosis, mechanisms and management.Frontiers in immunology · 2025Review
- [Clinical research progress of lusutrombopag for the treatment of thrombocytopenia in chronic liver disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024Review
- Article
- Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review.ImmunoTargets and therapy · 2024Review
- A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome.Frontiers in medicine · 2024Review
- Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines.World journal of gastrointestinal surgery · 2023Review
- Rituximab resistance in ITP and beyond.Frontiers in immunology · 2023Review
- Application and investigation of thrombopoiesis-stimulating agents in the treatment of thrombocytopenia.Therapeutic advances in hematology · 2023Review
- Thrombocytopenia in chronic liver disease: Physiopathology and new therapeutic strategies before invasive procedures.World journal of gastroenterology · 2022Review
- Review
- Quantitative systems pharmacology model of thrombopoiesis and platelet life-cycle, and its application to thrombocytopenia based on chronic liver disease.CPT: pharmacometrics & systems pharmacology · 2021Article
- Efficacy of Lusutrombopag for Thrombocytopenia in Patients with Chronic Liver Disease Scheduled to Undergo Invasive Procedures.Internal medicine (Tokyo, Japan) · 2021Article
- Emerging Therapies in Immune Thrombocytopenia.Journal of clinical medicine · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lusutrombopag (Mulpleta®) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels. In September 2015, lusutrombopag received its first global approval in Japan for the improvement of CLD-associated thrombocytopenia in patients scheduled to undergo elective invasive procedures. This article summarizes the milestones in the development of lusutrombopag leading to this first approval.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.